Sandoz's Enbrel Biosimilar Gets FDA Staff Nod
Staff at the U.S. Food and Drug Administration on Monday gave a thumbs-up to Sandoz Inc.'s proposed biosimilar of Amgen Inc.'s immunosuppressant Enbrel, clearing the drug's path at an advisory committee...To view the full article, register now.
Already a subscriber? Click here to view full article